OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Ocugen, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.79+0.01 (+0.90%)
Close on Oct 19, 2026
- Market cap
- $266.64M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
42.8%
145M of 339M shares
Institutional holders
147
43 new, 31 sold out
Net institutional buying
34M
In Q2 2026
Insider trades, 12 months
1 buys · 2 sales
Net sold $563.28K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 26,952,492 | 8.00% | 13G (passive) | Jun 30, 2026 |
| State Street Corporation | 21,469,307 | 6.30% | 13G (passive) | Jun 30, 2026 |
| Janus Henderson Group PLC | 20,000,000 | 6.00% | 13G (passive) | Nov 28, 2025 |
| Millennium Management LLC | 17,074,584 | 5.20% | 13G (passive) | Apr 9, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OCGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 27,002,933 | 7.96% | $41.31M | +19,697,954 | 0.00% |
| State Street Corp | 21,469,307 | 6.33% | $32.85M | +11,799,116 | 0.00% |
| Vanguard Capital Management LLC | 14,372,598 | 4.24% | $21.99M | +568,487 | 0.00% |
| Millennium Management LLC | 13,943,252 | 4.11% | $21.33M | +216,060 | 0.01% |
| Geode Capital Management, LLC | 8,871,013 | 2.62% | $13.58M | +4,643,909 | 0.00% |
| Rtw Investments, LP | 6,666,666 | 1.97% | $10.20M | – | 0.09% |
| UBS Group AG | 5,177,508 | 1.53% | $7.92M | −2,102,812 | 0.00% |
| Ikarian Capital, LLC | 3,962,972 | 1.17% | $6.06M | – | 0.65% |
| Gmt Capital Corp | 3,505,398 | 1.03% | $5.36M | – | 0.28% |
| Marshall Wace, Llp | 3,410,257 | 1.01% | $5.22M | −4,642,093 | 0.00% |
| Vanguard Portfolio Management LLC | 3,329,446 | 0.98% | $5.09M | +2,393,647 | 0.00% |
| Hennion & Walsh Asset Management, Inc. | 2,830,397 | 0.83% | $4.33M | +1,553,672 | 0.12% |
| Northern Trust Corp | 2,747,562 | 0.81% | $4.20M | +2,033,826 | 0.00% |
| Vanguard Fiduciary Trust Co | 2,367,144 | 0.70% | $3.62M | +366,041 | 0.00% |
| Two Sigma Investments, LP | 2,230,179 | 0.66% | $3.41M | −21,103 | 0.00% |
| Qube Research & Technologies Ltd | 2,203,407 | 0.65% | $3.37M | −1,569,659 | 0.00% |
| Bank Of America Corp /De/ | 1,990,636 | 0.59% | $3.05M | +816,456 | 0.00% |
| Hrt Financial LP | 1,768,297 | 0.52% | $2.71K | +1,391,703 | 0.00% |
| Boothbay Fund Management, LLC | 1,097,742 | 0.32% | $1.68M | – | 0.02% |
| Charles Schwab Investment Management Inc | 1,042,537 | 0.31% | $1.60M | +830,443 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 147 | 145M | 42.8% | 43 / 46 | 27 / 31 | 54M | 20M |
| Q1 2026 | 137 | 111M | 32.7% | 47 / 43 | 21 / 16 | 73M | 7M |
| Q4 2025 | 109 | 62M | 18.2% | 30 / 33 | 19 / 14 | 23M | 7M |
| Q3 2025 | 97 | 46M | 13.5% | 18 / 21 | 35 / 24 | 4M | 11M |
| Q2 2025 | 104 | 52M | 15.4% | 33 / 28 | 25 / 39 | 14M | 39M |
| Q1 2025 | 110 | 77M | 22.6% | 18 / 38 | 29 / 21 | 10M | 5M |
| Q4 2024 | 114 | 72M | 21.1% | 26 / 31 | 29 / 25 | 8M | 16M |
| Q3 2024 | 115 | 80M | 23.5% | 32 / 34 | 22 / 17 | 32M | 2M |
| Q2 2024 | 101 | 67M | 19.9% | 44 / 24 | 12 / 23 | 42M | 9M |
| Q1 2024 | 81 | 35M | 10.2% | 27 / 24 | 7 / 14 | 11M | 3M |
| Q4 2023 | 68 | 27M | 7.9% | 11 / 16 | 19 / 21 | 1M | 8M |
| Q3 2023 | 78 | 33M | 9.7% | 5 / 20 | 22 / 23 | 1M | 17M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of OCGN | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 13,986,418 | 4.12% | $21.40M | 0.20% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 10,177,094 | 3.00% | $15.57M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 8,719,964 | 2.57% | $13.34M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 3,882,893 | 1.15% | $5.94M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 3,707,354 | 1.09% | $4.56M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,209,874 | 0.65% | $3.38M | 0.02% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 1,818,215 | 0.54% | $2.78M | 0.10% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,704,694 | 0.50% | $2.35M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 1,147,893 | 0.34% | $1.76M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 996,712 | 0.29% | $1.52M | 0.01% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 931,671 | 0.27% | $1.29M | 0.01% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 830,799 | 0.24% | $1.02M | 0.01% | Jul 31, 2026 |
| iShares Genomics Immunology and Healthcare ETF | 723,783 | 0.21% | $890.25K | 0.47% | Jul 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 661,597 | 0.20% | $1.01M | 0.00% | Jun 30, 2026 |
| Master Small Cap Index Series | 638,829 | 0.19% | $977.41K | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Shankar Musunuri | Chief Executive Officer, Director | 5,575,232 | 1.64% | Sep 11, 2026 |
| Treerita Essalima Johnson-Greene | Chief Financial Officer | 521,350 | 0.15% | Jun 17, 2026 |
| Ramesh Ramachandran | Chief Accounting Officer | 209,100 | 0.06% | Jan 6, 2026 |
| Arun Upadhyay | See Remarks | 306,197 | 0.09% | Jan 6, 2025 |
| Huma Qamar | Chief Medical Officer | 1,643 | 0.00% | Jan 6, 2025 |
| Junge Zhang | Director | 2,369,569 | 0.70% | Jun 15, 2026 |
| Kirsten Castillo | Director | 75,000 | 0.02% | Jun 15, 2026 |
| Uday Kompella | Director | 705,090 | 0.21% | Jun 15, 2026 |
| Satishchandran Chandrasekhar | Director | – | – | Jun 15, 2026 |
| Blaise Coleman | Director | – | – | Jun 15, 2026 |
| Prabhavathi Fernandes | Director | 10,000 | 0.00% | Dec 2, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Shankar Musunuri Chief Executive Officer, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −57,264 | $1.12 | $64.14K | 1,088,035 |
| Shankar Musunuri Chief Executive Officer, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −468,727 | $1.12 | $524.97K | 4,487,197 |
| Treerita Essalima Johnson-Greene Chief Financial Officer | Jun 15, 2026 | Buy | +21,000 | $1.23 | $25.83K | 521,000 |
| Junge Zhang Director | Apr 1, 2026 | Option exercise | +112,205 | $0.46 | $51.61K | 1,292,387 |
| Junge Zhang Director | Apr 1, 2026 | Option exercise | +15,000 | $0.51 | $7.65K | 1,180,182 |
| Junge Zhang Director | Apr 1, 2026 | Option exercise | +66,929 | $1.42 | $95.04K | 1,359,316 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 2, 2026 | Award | +3,123,201 | – | – | 4,955,924 |
| Ramesh Ramachandran Chief Accounting Officer | Jan 2, 2026 | Award | +207,300 | – | – | 209,100 |
| Arun Upadhyay See Remarks | Jan 3, 2025 | Tax withholding | −41,633 | $0.89 | $37.05K | 306,197 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 3, 2025 | Tax withholding | −177,146 | $0.89 | $157.66K | 1,832,723 |
| Prabhavathi Fernandes Director | Nov 26, 2024 | Buy | +10,000 | $0.91 | $9.10K | 10,000 |
| Kirsten Castillo Director | Nov 22, 2024 | Buy | +25,000 | $0.91 | $22.75K | 75,000 |
| Arun Upadhyay See Remarks | Sep 16, 2024 | Tax withholding | −842 | $1.17 | $985 | 347,830 |
| Arun Upadhyay See Remarks | Jun 17, 2024 | Tax withholding | −917 | $1.42 | $1.30K | 348,672 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 3, 2024 | Tax withholding | −180,204 | $0.65 | $117.13K | 2,009,869 |
| Arun Upadhyay See Remarks | Jan 3, 2024 | Tax withholding | −41,633 | $0.65 | $27.06K | 349,589 |
| Arun Upadhyay See Remarks | Sep 16, 2023 | Tax withholding | −842 | $0.41 | $345 | 391,222 |
| Arun Upadhyay Chief Scientific Officer | Jun 16, 2023 | Tax withholding | −917 | $0.51 | $468 | 392,064 |
| Junge Zhang Director | Jun 14, 2023 | Buy | +200,278 | $0.50 | $100.14K | 1,077,182 |
| Shankar Musunuri Chief Executive Officer, Director | Feb 16, 2023 | Sale(10b5-1 plan) | −100,000 | $1.08 | $108.00K | 2,190,073 |
| Shankar Musunuri Chief Executive Officer, Director | Feb 16, 2023 | Option exercise | +100,000 | $0.33 | $33.00K | 2,290,073 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 17, 2023 | Option exercise | +100,000 | $0.51 | $51.00K | 2,327,950 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 17, 2023 | Sale(10b5-1 plan) | −100,000 | $1.28 | $128.00K | 2,227,950 |
| Jessica Crespo CAO/SVP, Finance | Jan 3, 2023 | Tax withholding | −1,913 | $1.25 | $2.39K | 161,478 |
| Arun Upadhyay Chief Scientific Officer | Jan 3, 2023 | Tax withholding | −7,102 | $1.25 | $8.88K | 392,981 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 3, 2023 | Tax withholding | −37,877 | $1.25 | $47.35K | 2,190,073 |
| Jessica Crespo CAO/SVP, Finance | Jan 3, 2023 | Award | +122,951 | – | – | 163,391 |
| Arun Upadhyay Chief Scientific Officer | Jan 3, 2023 | Award | +315,924 | – | – | 400,083 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 3, 2023 | Award | +1,475,410 | – | – | 2,227,950 |
| Shankar Musunuri Chief Executive Officer, Director | Dec 16, 2022 | Option exercise | +95,809 | $0.51 | $48.86K | 848,349 |
| Shankar Musunuri Chief Executive Officer, Director | Dec 16, 2022 | Sale(10b5-1 plan) | −95,809 | $1.43 | $137.01K | 752,540 |
| Shankar Musunuri Chief Executive Officer, Director | Oct 14, 2022 | Sale(10b5-1 plan) | −100,000 | $1.66 | $166.00K | 752,540 |
| Shankar Musunuri Chief Executive Officer, Director | Oct 14, 2022 | Option exercise | +100,000 | $0.51 | $51.00K | 852,540 |
| Ramesh Kumar Director | Oct 6, 2022 | Sale(10b5-1 plan) | −4,500 | $1.83 | $8.24K | 0 |
| Ramesh Kumar Director | Oct 6, 2022 | Option exercise | +4,500 | $0.51 | $2.30K | 4,500 |
| Kirsten Castillo Director | Aug 11, 2022 | Option exercise | +42,000 | $0.28 | $11.76K | 92,000 |
| Kirsten Castillo Director | Aug 11, 2022 | Sale | −42,000 | $2.91 | $122.22K | 50,000 |
| Ramesh Kumar Director | Jul 18, 2022 | Option exercise | +7,500 | $0.51 | $3.83K | 7,500 |
| Ramesh Kumar Director | Jul 18, 2022 | Sale(10b5-1 plan) | −7,500 | $2.57 | $19.28K | 0 |
| Shankar Musunuri Chief Executive Officer, Director | Jul 14, 2022 | Sale(10b5-1 plan) | −150,000 | $2.72 | $408.00K | 752,540 |
| Shankar Musunuri Chief Executive Officer, Director | Jul 14, 2022 | Option exercise | +150,000 | $0.33 | $49.50K | 902,540 |
| Shankar Musunuri Chief Executive Officer, Director | May 13, 2022 | Sale(10b5-1 plan) | −125,000 | $1.92 | $240.00K | 752,540 |
| Shankar Musunuri Chief Executive Officer, Director | May 13, 2022 | Option exercise | +125,000 | $0.33 | $41.25K | 877,540 |
| Ramesh Kumar Director | Apr 18, 2022 | Sale(10b5-1 plan) | −7,500 | $2.83 | $21.23K | 0 |
| Ramesh Kumar Director | Apr 18, 2022 | Option exercise | +7,500 | $0.51 | $3.83K | 7,500 |
| Jessica Crespo CAO/SVP, Finance | Mar 18, 2022 | Award | +22,940 | – | – | 40,440 |
| Shankar Musunuri Chief Executive Officer, Director | Mar 16, 2022 | Option exercise | +81,823 | $0.33 | $27.00K | 834,363 |
| Shankar Musunuri Chief Executive Officer, Director | Mar 16, 2022 | Sale(10b5-1 plan) | −81,823 | $2.65 | $216.83K | 752,540 |
| Junge Zhang Director | Mar 3, 2022 | Option exercise | +39,000 | $0.51 | $19.89K | 39,000 |
| Junge Zhang Director | Mar 3, 2022 | Option exercise | +49,000 | $1.83 | $89.67K | 88,000 |
| Shankar Musunuri Chief Executive Officer, Director | Feb 14, 2022 | Sale(10b5-1 plan) | −90,000 | $3.74 | $336.60K | 752,540 |
| Shankar Musunuri Chief Executive Officer, Director | Feb 14, 2022 | Option exercise | +90,000 | $0.33 | $29.70K | 842,540 |
| Ramesh Kumar Director | Jan 18, 2022 | Option exercise | +7,500 | $0.51 | $3.83K | 7,500 |
| Ramesh Kumar Director | Jan 18, 2022 | Sale(10b5-1 plan) | −7,500 | $4.07 | $30.53K | 0 |
| Sanjay Subramanian Chief Financial Officer | Jan 3, 2022 | Award | +125,534 | – | – | 161,125 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 3, 2022 | Award | +346,540 | – | – | 752,540 |
| Manish Potti Director | Dec 16, 2021 | Option exercise | +31,500 | $1.83 | $57.65K | 45,000 |
| Manish Potti Director | Dec 16, 2021 | Option exercise | +13,500 | $0.51 | $6.89K | 13,500 |
| Shankar Musunuri Chief Executive Officer, Director | Dec 16, 2021 | Sale(10b5-1 plan) | −115,000 | $5.22 | $600.30K | 1,145,299 |
| Junge Zhang Director | Nov 16, 2021 | Option exercise | +1,653 | $7.56 | $12.50K | 876,904 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Musunuri Shankar Officer | Oct 9, 2026 | 525,991 | $497.96K | Oct 9, 2026 | Equity Compensation |
| Musunuri Shankar Officer | Sep 9, 2026 | 525,991 | $589.74K | Sep 9, 2026 | Equity Compensation |
| C. Whittington Marna Director | Jul 9, 2025 | 112,205 | $122.89K | Jul 9, 2025 | Stock Option Exercise |
| Fernandes Prabhavathi Director | Jun 11, 2025 | 146,705 | $171.03K | Jun 11, 2025 | Stock Option Exercise |
| Kumar Ramesh Director | Aug 16, 2024 | 116,705 | $145.90K | Aug 16, 2024 | Stock Option Exercise |